Experimental autoimmune uveitis is an immune mediated inflammation of the retina and uveal tract. 
Eye (1992) 6, [447] [448] [449] [450] [451] [452] epitopes that bind to antibodies (antibody-binding epi topes), induce disease (pathogenic epitopes) or stimulate T-lymphocytes to proliferate (proliferative epitopes). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The clinical and histopathological features of EAU induced by both of these proteins and by their synthetic pathogenic peptides are very similar and bear a close resemblance to endogenous clinical uveitis in humans.17 EAU thus serves as an excellent animal model for clinical uveitis. Considerable information on the immunopatho genesis and pathology of autoimmune uveitis has been obtained using this model. It is now being studied to develop strategies for immune intervention in uveitis, i.e. to induce a state of immune unresponsiveness or tolerance such that the T-lymphocytes are rendered incapable of recognising the retinal antigens and mounting an immun ological response.
We attempted to induce tolerance to SAg and IRBP by parenteral administration of very small quantities of these antigens coupled to spleen cells. This method has been shown to be effective in the animal model of experimental allergic encephalomyelitis (EAE ), another T-helper lym phocyte mediated autoimmune disorder, induced by mye lin basic protein. 1 8 ,19 We also used this method to test several peptides of SAg in order to find one or more pep tides that would successfully prevent the induction of EAU. Synthetic peptides of SAg corresponding to the known 'antibody-binding', 'pathogenic' and 'prolifera tive' epitopes were coupled to spleen cells and admin istered to inbred (syngeneic) Lewis rats. The tolerising effect of these peptides against immunisation with the complete molecule of SAg was studied. The results of these studies are presented.
MATERIALS AND METHODS

Preparation of Retinal Antigens and Synthetic Peptides
Both SAg and IRBP were obtained and purified from Table I , corre sponding to its known 'antibody-binding', 'pathogenic' and 'proliferative' epitopes were synthesised by conven tional solid phase techniques as described before.12
Coupling of SAg, Peptides and IRBP to Spleen Cells
One hundred and eleven female Lewis rats, 6-8 weeks old, were used in this experiment. Erythrocyte-free spleen cell suspensions were obtained from inbred (syngeneic) ani mals, washed in phosphate-buffered saline and mixed with 500 mg/ml solution of SAg, synthetic peptides or IRBP; or with saline without any protein (sham coating for controls). A freshly made solution of ethyl-dimethyl-ami nopropyl-carbodiimide (ECDI) 100 mg/ml was used chemically to couple the antigens or peptides to spleen cells. After thorough washing the cells were resuspended in a final concentration of 1 x 10 8 cells in 0.2 ml saline. Each animal received 0.2 ml of the coated or sham coated cells intravenously in the tail vein, under ketamine anaes thesia. Five days later the animals were immunised with antigen and adjuvants as indicated in Tables II-V.
Clinicopathological Assessment of EAU
One week following immunisation the rats were observed daily for development ofEAU by slit lamp biomicroscopy. The appearance of uveitis was noted and graded on a scale of 0 to 4. Serum samples from all animals were obtained prior to immunisation and on day 21 post-immunisation. These were tested for the presence of anti-SAg or anti IRBP antibodies by the enzyme-linked immunosorbent assay (E LISA).22 Animals were killed on day 21 post immunisation. The eyes removed, fixed in formalin and examined histologically.
RESULTS
Inhibition of SAg-and IRBP-Induced EAU
Both retinal proteins, SAg and IRBP, when coupled to spleen cells and administered intravenously, successfully induced a state of tolerance in animals. These animals showed minimal clinical and histological changes of uvei tis (T able II). Clinically the onset of uveitis was delayed and severity was mild. Histopathologically, uveal inflam mation was manifest as a few scattered vitreous cells and some perivascular infiltration of the retinal vessels. The photoreceptor layer was notably intact in all animals ( Fig. la) . The tolerance was very specific for the antigen used. Neither of the proteins afforded cross protection against immunisation with the other protein ( Fig. 1 b) . All control animals showed severe clinical and histopath ological uveitis.
Antibody Responses
The anti-SAg and anti-IRBP antibody activity observed in serum samples of the animals is shown in Fig. 2 . The anti body response was predominantly against the antigen used to challenge the animals, irrespective of the antigen coupled to spleen cells and administered prior to chal lenge. Animals challenged with SAg showed a marked anti-SAg response with minimal anti-IRBP activity. Similarly, animals challenged with IRBP showed a marked anti-IRBP response and insignificant anti-SAg activity_ All animals, with and without uveitis, showed an antibody response to one or other antigen.
Peptide Inhibition of SAg-Induced Uveitis
None of the 'antibody-binding' peptides tested, peptides #649, #683 and #684, afforded any protection against
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SAg-induced EAU (T able III)_ Of the four 'pathogenic' peptides tested, only peptide 'N' (#674) showed con siderable tolerising effect (T able IV) in terms of number of animals affected, time of onset and clinical and histologi cal severity of uveitis_ Peptide #673, corresponding to a 'proliferative' and 'pathogenic' epitope of SAg, showed a very marked tolerising effect (T able V). None of the ani mals tolerised with this peptide of SAg and subsequently challenged with whole SAg showed clinical dr histologi cal signs of uveitis. All controls that were sham tolerised and challenged with SAg developed severe clinical and histological uveitis (Fig_ 3).
DISCUSSION
The entire range of clinical and pathological changes that occur in chronic endogenous uveitis in humans can be reproduced in animals following immunisation with ret inal SAg and IRBP"7 The ability to downregulate the host's immune response and an understanding of the mechanisms involved in such immunomodulation will help us develop protocols for immune intervention in human uveitis_ Previous studies on tolerisin & animals against EAU have used SAg as the sensitising agent,22-25 Similar tolerance to the more potent retinal autoantigen IRBP has not been described. We tested a different and novel method of tolerising Lewis rats to both these retinal autoantigens and their pep tides by the intravenous administration of antigen coupled to spleen cells 5 days before immunisation with the respective antigens_ This method of inducing antigen specific T-cell tolerance has been well characterised with regard to experimental autoimmune encephalomyelitis (EAE), an autoimmune disease of the central nervous system caused by immunisation with myelin basic protein (MBP) and its peptides_18•19 With regard to SAg and IRBP we demonstrated that the administration of antigen-coated spleen cells markedly downregulated the animal's response to a challenging dose of the same antigen, result ing in an attenuation of the induced clinical and histologi cal disease. This effect was very specific for the antigen used and did not confer protection against the other retinal antigen_ Tolerance achieved by coupling antigen to spleen cells is believed to occur via two mechanisms: the induc tion of T-helper lymphocyte anergy and an increase in T-suppressor lymphocyte activity.26-29 When a T-helper lymphocyte encounters antigen on an antigen-presenting cell (APC) such as spleen cells, it needs another signal, called the co-stimulatory signal, from the APC to become activated and produce interleukin-2. Interleukin-2 is a substance (lymphokine) produced by activated T-Iympho cytes. This is required for the recruitment of other cells of the cell-mediated immune response. However, when anti gen is presented but the co-stimulatory signal is lacking from the APC, as is the case with spleen cells coated with antigen but chemically treated with ECDI, instead of becoming activated, the T-helper lymphocytes pass into a state of anergy for a period of several days and become incapable of producing interleukin-2. A second challenge with antigen during the period of anergy will therefore not trigger the immune response and uveitis will not occur. In this study we were able successfully to apply this mode of inducing immune tolerance to the two retinal autoantigens SAg and IRBP. Coupled to spleen cells and administered to Lewis rats, both antigens were able to downregulate EAU in a very specific manner. We extended our experiments to study the tolerising effects, if any, of synthetic peptides corresponding to the 'patho genic', 'proliferative' and 'antibody-binding' epitopes of SAg. Of the known pathogenic epitopes of SAg, peptide 'N' (#674) showed the maximal tolerising effect against induction of EAU following immunisation with SAg. The other pathogenic peptides, peptide 'M' (#676), #679 and #680, conferred only partial protection against SAg induced EAU as is true of animals tolerised by oral feed ing with SAg. 23 The most conclusive protection, however, was afforded by the peptide #673. Interestingly this pep tide lies adjacent to the 'pathogenic' peptide 'N' (#674) on its N-terminus side with an overlap of 10 amino acids. This region of the SAg molecule between amino acid positions 273 and 302 therefore appears to be important in the development of SAg-induced EAU. Tolerising ani mals with peptides corresponding to this region confers protection against subsequent immunisations with the complete SAg molecule and is similar to the protection afforded by tolerising animals with the complete SAg molecule. These results would indicate that the region between amino acids 273 and 302 is the immunodominant region relative to the regions corresponding to other pep tides studied.
The presence of an active antibody response in associ ation with a suppression of T-cell activity may seem anomalous but is consistent with the accepted theory of T-cell anergy described above. Binding of antigen to an antigen-specific receptor on the T-Iymphocyte in the absence of a co-stimulatory signal is sufficient stimulus to induce the cell to produce the lymphokine interleukin-4 (IL4). IL4 in tum helps B-cells to secrete antibody . This would allow antibody production in the absence ofT-cell mediated pathogenic effects as shown in our study. The marked antibody response shown by all animals with and without EAU would suggest that the humoral immune response does not play an important role in the induction of tolerance to SAg or IRBP.
This study has shown that retinal autoantigens coupled to spleen cells can be used successfully to induce tolerance against retinal antigen-induced EAU. This is an effective method of inducing tolerance in which the dose of the tolerising antigen required is small and can be admin istered in a controlled manner. Our study has also revealed an immunodominant region of SAg corresponding to pep tides #673 and #674 (positions 273-302). The discovery of an immunodominant region will have relevance in evolving strategies for peptide therapy of EAU. b Peptide #673 is a 'pathogenic' peptide.
